Read the Beforeitsnews.com story here. Advertise at Before It's News here.
Profile image
By Streetwise-The Energy Report (Reporter)
Contributor profile | More stories
Story Views
Now:
Last hour:
Last 24 hours:
Total:

Orca Energy Group Rated Hold: Tanzania Exit and Capital Return Strategy Signal Major Strategic Shift

% of readers think this story is Fact. Add your two cents.


Source: Bill Newman 04/17/2026

Research Capital maintained a Hold rating on Orca Energy Group Inc. (ORC.B:TSXV; ORXGF:OTCMKTS), following the company’s agreement to sell its Tanzanian Songo Songo business for nominal consideration.

In a research note published on April 14, 2026, Bill Newman, CFA of Research Capital Corporation, maintained a Hold rating on Orca Energy Group Inc. (ORC.B:TSXV; ORXGF:OTCMKTS), with no target price currently in place pending additional clarity from year-end results and pre-close cash extraction.

Newman views the transaction as a de-risking event that transitions Orca from an operating exploration and production company to a capital return story, while noting limited remaining upside beyond near-term cash distributions.

Transaction Overview

Orca Energy Group Inc. announced it has entered into a definitive agreement to sell its wholly owned subsidiary, PAEM — which holds all Tanzanian assets and liabilities through its operating entity, PAET — to a consortium led by Amber Energy (51%) and Taifa Gas (49%) for nominal consideration of US$10. The purchaser will assume all associated obligations, including ongoing litigation, tax exposures, and future development commitments related to the Songo Songo gas asset.

Orca retains the right to extract cash prior to closing and may receive a portion of certain extraordinary income generated between signing and closing. Following completion, Orca will have no ongoing interest in the Tanzanian business. The transaction remains subject to customary closing conditions, including Tanzanian government approvals and the release of certain guarantees. Shareholder approval by a simple majority is also required, and major shareholder Shaymar Limited has indicated its support.

Valuation and Distributable Capital

Research Capital estimates Orca’s residual equity value at approximately US$65.7 million, or CA$4.55 per share. The firm’s analysis begins with reported cash and cash equivalents of US$127.9 million as of September 30, 2025, and adjusts for US$43.3 million in dividends paid since that date — comprising a US$14.4 million special dividend paid October 6, 2025 and a US$28.9 million special dividend paid March 2, 2026. After these payments, net cash stands at approximately US$84.6 million.

Deducting US$24.7 million in restricted cash related to an ongoing legal judgment reduces net usable cash to approximately US$59.9 million. Adding estimated Q4/25 free cash flow of US$11.9 million and subtracting US$1.1 million for the IFC participating interest and approximately US$5.0 million in estimated pre-close costs yields the residual equity estimate of US$65.7 million (CA$4.55/share). The analyst notes this is a preliminary estimate and will be revisited following year-end results.

On a forward-looking basis, Research Capital estimates Orca could generate approximately US$16.7 million (CA$1.23/share) in free cash flow during 2026, though this figure is excluded from the base case valuation given uncertainty around transaction timing and the company’s ability to extract cash prior to closing. It is characterized as potential incremental upside.

Strategic Context

Research Capital views the transaction positively, noting it “materially simplifies the Orca investment thesis, transitioning the Company from an operating E&P with significant geopolitical and regulatory risk to a capital return story anchored by its cash balance.”

With shares trading at CA$3.80 against a preliminary estimated residual value of CA$4.55 per share, the analyst observes that the stock appears broadly in line with current valuation.

Risks

The analyst highlights several material risks investors should consider. Transaction closing risk remains, as the divestiture requires Tanzanian government approvals and guarantee releases, and any delay or failure to close would leave Orca exposed to ongoing operational, regulatory, and legal risks in Tanzania. Pre-close cash extraction risk is also significant, as the valuation assumes Orca can successfully upstream a substantial portion of its cash balance prior to closing — an outcome that could be constrained by regulatory requirements or repatriation limitations.

Additional risks include variability in wind-down and legal costs, uncertainty surrounding the AGS appeal outcome, potential fluctuations in the IFC participating interest payment, and foreign exchange and repatriation risk given that a portion of cash flow is denominated in Tanzanian shillings.

Outlook

Research Capital maintains its Hold rating and does not currently publish a price target, citing the need for additional clarity from year-end results (expected April 24, 2026) and greater visibility on pre-close cash extraction.

At the current share price of CA$3.80, the stock trades at a modest discount to the analyst’s preliminary residual equity estimate of CA$4.55 per share.

Sign up for our FREE newsletter at: www.streetwisereports.com/get-news

Important Disclosures:

  1. This article does not constitute investment advice and is not a solicitation for any investment. Streetwise Reports does not render general or specific investment advice and the information on Streetwise Reports should not be considered a recommendation to buy or sell any security. Each reader is encouraged to consult with his or her personal financial adviser and perform their own comprehensive investment research. By opening this page, each reader accepts and agrees to Streetwise Reports’ terms of use and full legal disclaimer. Streetwise Reports does not endorse or recommend the business, products, services or securities of any company.

For additional disclosures, please click here.

Disclosures for Research Capital Corp., Orca Energy Group Inc., April 14, 2026

Analyst Certification I, Bill Newman, CFA, certify the views expressed in this report were formed by my review of relevant company data and industry investigation, and accurately reflect my opinion about the investment merits of the securities mentioned in the report. I also certify that my compensation is not related to specific recommendations or views expressed in this report. Each analyst of Research Capital Corporation whose name appears in this report hereby certifies that (i) the recommendations and opinions expressed in this research report accurately reflect the analyst’s personal views and (ii) no part of the research analyst’s compensation was or will be directly or indirectly related to the specific conclusions or recommendations expressed in this research report. Relevant Disclosures Applicable to Companies Under Coverage Information about Research Capital Corporation’s Rating System, the distribution of our research to clients and the percentage of recommendations which are in each of our rating catergories is available on our website at www.researchcapital.ca General Disclosures Research Capital Corporation publishes research and investment recommendations for the use of its clients. The opinions, estimates and projections contained in all Research Reports published by Research Capital Corporation (“RCC”) are those of RCC as of the date of publication and are subject to change without notice. RCC makes every effort to ensure that the contents have been compiled or derived from sources believed to be reliable and that contain information and opinions that are accurate and complete; RCC makes no representation or warranty, express or implied, in respect thereof, takes no responsibility for any errors and omissions which may be contained therein and accepts no liability whatsoever for any loss arising from any use of or reliance on its Research Reports or its contents. Information may be available to RCC that is not contained therein. Contents of this report cannot be reproduced in whole or in part without the express permission of Research Capital Corporation. Research Reports disseminated by RCC are not a solicitation to buy or sell. All securities not available in all jurisdictions. Distribution Policy Through www.researchcapital.com, our institutional and corporate clients can access our research as soon as it becomes available, 24-7. New reports are continually uploaded to the site as they become available throughout the day. Clients may also receive our research via Reuters, Bloomberg, FactSet, and Capital IQ. All of our research is made widely available at the same time to all Research Capital client groups entitled to our research. In addition, research reports are sent directly to our clients based on their delivery preference (mail, fax, e-mail). Fair Dissemination of Research Reports and Ratings To the extent reasonably practicable, Research Reports will be disseminated contemporaneously to all of Research Capital Corporation (“RCC”) customers who are entitled to receive the firm’s research. Until such time, Research Analysts will not discuss the contents of their reports with Sales and Trading or Investment Banking employees. RCC equity research is posted to our proprietary website to ensure eligible clients receive coverage initiations and changes in rating, targets and opinions in a timely manner. Additional distribution may be done by the sales personnel via email, fax or regular mail. Please contact your Investment Advisor or Portfolio Manager for more information regarding RCC research. Percentage Distribution of Research Ratings As required by the Canadian Investment Regulatory Organization, Research Capital provides a summary of the percentage of its recommendations that fall into each category of our ratings. Our distribution of ratings is available on our website at www.researchcapital.com Information regarding our categories of recommendations, quarterly summaries of the percentage of our recommendations which fall into each category and our policies regarding the release of our research reports is available at www.researchcapital.com or may be requested by contacting the analyst. Potential Conflicts of Interest All Research Capital Corporation (“RCC”) Analysts are compensated based in part on the overall revenues of RCC, a portion of which are generated by investment banking activities. RCC may have had, or seek to have, an investment banking relationship with companies mentioned in this report. RCC and/or its officers, directors and employees may from time to time acquire, hold or sell securities mentioned in our Research Reports as principal or agent. RCC makes every effort possible to avoid conflicts of interest, however readers should assume that a conflict might exist, and therefore not rely solely on this report when evaluating whether or not to buy or sell the securities of subject companies. Research Capital Corporation, its directors, officers and other employees may, from time to time, have positions in the securities mentioned herein. RC USA INC. US Institutional Clients – Research Capital USA Inc., a wholly owned subsidiary of Research Capital Corporation, accepts responsibility for the contents of this report. This report has been created by analysts who are employed by Research Capital Corporation, a Canadian Investment Dealer. US firms or institutions receiving this report should effect transactions in securities discussed in the report through Research Capital USA Inc., a Broker – Dealer registered with the Financial Industry Regulatory Authority (FINRA). Member – Canadian Investor Protection Fund / membre – fonds canadien de protection des épargnants

( Companies Mentioned: ORC.B:TSXV;ORXGF:OTCMKTS, )


Source: https://www.streetwisereports.com/article/2026/04/17/orca-energy-group-rated-hold-tanzania-exit-and-capital-return-strategy-signal-major-strategic-shift.html


Before It’s News® is a community of individuals who report on what’s going on around them, from all around the world.

Anyone can join.
Anyone can contribute.
Anyone can become informed about their world.

"United We Stand" Click Here To Create Your Personal Citizen Journalist Account Today, Be Sure To Invite Your Friends.

Before It’s News® is a community of individuals who report on what’s going on around them, from all around the world. Anyone can join. Anyone can contribute. Anyone can become informed about their world. "United We Stand" Click Here To Create Your Personal Citizen Journalist Account Today, Be Sure To Invite Your Friends.


LION'S MANE PRODUCT


Try Our Lion’s Mane WHOLE MIND Nootropic Blend 60 Capsules


Mushrooms are having a moment. One fabulous fungus in particular, lion’s mane, may help improve memory, depression and anxiety symptoms. They are also an excellent source of nutrients that show promise as a therapy for dementia, and other neurodegenerative diseases. If you’re living with anxiety or depression, you may be curious about all the therapy options out there — including the natural ones.Our Lion’s Mane WHOLE MIND Nootropic Blend has been formulated to utilize the potency of Lion’s mane but also include the benefits of four other Highly Beneficial Mushrooms. Synergistically, they work together to Build your health through improving cognitive function and immunity regardless of your age. Our Nootropic not only improves your Cognitive Function and Activates your Immune System, but it benefits growth of Essential Gut Flora, further enhancing your Vitality.



Our Formula includes: Lion’s Mane Mushrooms which Increase Brain Power through nerve growth, lessen anxiety, reduce depression, and improve concentration. Its an excellent adaptogen, promotes sleep and improves immunity. Shiitake Mushrooms which Fight cancer cells and infectious disease, boost the immune system, promotes brain function, and serves as a source of B vitamins. Maitake Mushrooms which regulate blood sugar levels of diabetics, reduce hypertension and boosts the immune system. Reishi Mushrooms which Fight inflammation, liver disease, fatigue, tumor growth and cancer. They Improve skin disorders and soothes digestive problems, stomach ulcers and leaky gut syndrome. Chaga Mushrooms which have anti-aging effects, boost immune function, improve stamina and athletic performance, even act as a natural aphrodisiac, fighting diabetes and improving liver function. Try Our Lion’s Mane WHOLE MIND Nootropic Blend 60 Capsules Today. Be 100% Satisfied or Receive a Full Money Back Guarantee. Order Yours Today by Following This Link.


Report abuse

Comments

Your Comments
Question   Razz  Sad   Evil  Exclaim  Smile  Redface  Biggrin  Surprised  Eek   Confused   Cool  LOL   Mad   Twisted  Rolleyes   Wink  Idea  Arrow  Neutral  Cry   Mr. Green

MOST RECENT
Load more ...

SignUp

Login